RenaSci

Obesity/Diabetes Publications

Manuscripts

Fernandez-Bueno I et al. Histologic characterization of retina neuroglia modifications in diabetic Zucker Diabetic Fatty rats. Invest Ophthalmol Vis Sci 58(11): 4925-4933, 2017. [PubMed] 

Galvin O et al. A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo. J Control Release 233: 198-207, 2016. [PubMed]

Vickers SP et al. New drug design and therapeutic development for weight reduction: Preclinical studies and clinical trials. In: Cardiovascular & Metabolic Disease: Scientific Discoveries and New Therapies. P. Peplow et al.  (Eds),  RSC Drug Discovery Series No. 45, The Royal Society of Chemistry, pp90-116, 2015. doi. 10.1039/9781782622390. Please click here for abstract.

Bryne FM et al. Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments. J Diabetes Res 2015. Available online: doi.10.1155/2015/752481. [PubMed]

Moser C et al. Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice. Phytomedicine 21: 1382-1389, 2014. [PubMed]

Vickers SP et al. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 7: 265-275, 2014. [PubMed]

Jones RB et al. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats. Eur J Pharmacol 729: 59-66, 2014. [PubMed]

Heal DJ et al. A review of late-stage CNS drug candidates for the treatment of obesity. Int J Obes 37(1): 107-117, 2013. [PubMed]

Cheetham SC and Jackson HC. Rodent models to evaluate anti-obesity drugs. In: TRP Channel Targets for Drugs and Toxins, Volume II. A Szallasi and T Bíró (Eds), Methods in Pharmacology and Toxicology, Volume I, Springer Protocols, Humana Press, pp351-376, 2012.  

Klein T et al. Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine. Diabetes Obes Metab 14(11): 1050-1053, 2012. [PubMed]

Heal DJ et al. Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity. In: Current Antipsychotics, Handb Exp Pharmacol Vol 212, G Gross and MA Geyer (Eds), Springer, pp135-164, 2012. [PubMed]

Vickers SP et al. Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: A comparison in naive and exenatide-treated animals. Clin Lab 58: 787-799, 2012. [PubMed]

Vickers SP and Clifton PG. Animal models to explore the effects of CNS drugs on food intake and energy expenditure. Neuropharmacology 63 (Issue 1): 124-131, 2012. [PubMed]

Heal DJ et al. What is the prognosis for new centrally-acting anti-obesity drugs. Neuropharmacology 63 (Issue 1): 132-146, 2012. [PubMed]

Poucher SM et al. Effects of saxagliptin and sitagliptin on glycemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes Obes Metab 14(10): 918-926, 2012. [PubMed]

Lynch CJ et al. Some cannabinoid receptor ligands and their distomers are direct acting openers of SUR1 KATP channels. Am J Physiol Endocrinol Metab. 302(5):E540-E551, 2012. [PubMed]

Vickers SP et al. The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol 164: 1248-1262, 2011. [PubMed]

Heal D et al. The 5-HT6 receptor as a target for developing novel antiobesity drugs. In: International Journal of Neurobiology, Vol 96, F Borsini (Ed), Academic Press, pp 73-109, 2011. [PubMed]

Gardiner JV et al. Prokineticin 2 is a hypothalamic neuropeptide that potently inhibits food intake. Diabetes 59: 397-406, 2010. [PubMed]

Heal DJ et al. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 68: 861-874, 2009. [PubMed]

Heal DJ et al. Selective 5-HT6 ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.  Pharmacol Ther 117: 207-231, 2008. [PubMed]

Vickers SP and Cheetham SC. Preclinical developments in anti-obesity drugs.  In: Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs, T Kirkham and S Cooper (Eds), Academic Press, pp 323-336, 2007.

Posters

Cheetham SC et al. Evaluation of elafibranor in the choline-deficient diet mouse model of NASH. NASH Summit Europe, Frankfurt, Germany, 10th-12th October 2017. View poster

Burkey BF et al. The MetAP2 inhibitor ZGN-1061 improves glycaemia in high-fat diet-induced obese mice. Program No. 845. 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), Lisbon, Portugal, 11th to 15th September, 2017. View poster

Fernandez-Bueno I et al. Characterization of early retinal degeneration in ZDF rats, a genetic model of type 2 diabetes. Abstract No. 2717-D0226. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Seattle, Washington, USA, 1st to 5th May, 2016. View poster

Galvin O et al. A sustained release formulation of novel quininib-hyaluronic acid microneedles inhibits angiogenesis and retinal vascular permeability in vivo. Abstract No. 4018-B0196. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Seattle, Washington, USA, 1st to 5th May, 2016. View poster

Cheetham SC et al. Markers of diabetic nephropathy in the ZDF rat model of diabetes. Abstract No. 572-P. American Diabetes Association 75th Scientific Sessions, Boston, Massachusetts, USA, 5th-9th June 2015. View poster

Hunt H et al. Evaluation of the antidiabetic effect of novel selective glucocorticoid antagonists in a model of cortisone-induced diabetes. Abstract No. 1240-P. American Diabetes Association 75th Scientific Sessions, Boston, Massachusetts, USA, 5th-9th June 2015. View poster

Headland KR et al. The effect of combination linagliptin and voglibose on glucose control and body weight. Abstract No. 1091-P. American Diabetes Association 73rd Scientific Sessions, Chicago, Illinois, USA, 21st-25th June 2013. View poster  

Vickers SP et al.  Effect of empagliflozin on body weight, glucose control and plasma parameters in STZ-induced diabetic rats fed a high-fat diet: comparison with exenatide. Poster No. 771. European Association for the Study of Diabetes (EASD), Berlin, Germany, 1st-5th October 2012. View poster

Byrne F et al.  Characterisation of the high fat diet/streptozotocin model of diabetes and the effects of the PPARɤ ligand pioglitazone. Abstract No. PF232. 14th World Congress on Pain, International Association for the Study of Pain, Milan, Italy. 27th-31st August 2012. View poster

Grempler R et al. The novel SGLT-2 inhibitor BI 10773 (empagliflozin) prevents pioglitazone-induced weight gain and further improves glycemic control in dietary-induced obese rats. Abstract No. 1851-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24th-28th June 2011. View poster

Lynch CJ et al. Potential role of direct K-ATP channel opening in the anti-diabetic actions of rimonabant and ibipinabant. Abstract No. 2011-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24th-28th June 2011.  View poster

Reiche D et al. Chronic administration of a new dual NEP/ECE inhibitor or lorsartan improves renal function in mice with diabetic nephropathy. Abstract No. 1011-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24th-28th June 2011.  View poster

Surman M et al. ALB-127158(a): An MCH1 receptor antagonist that exhibits weight loss and improvements in insulin sensitivity in diet-induced obese mice. Abstract No. 0108-LB. American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24th-28th June 2011.  View poster

Vickers SP et al. The DPP-4 inhibitor linagliptin is weight neutral in the DIO rat but inhibits the weight gain of DIO animals withdrawn from exenatide. Abstract No. 979-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24th-28th June 2011.  View poster 

Vickers SP et al. Effect of STZ dose and dosing regimen on the diabetes phenotype of C57BL/6J mice fed a high fat diet. Diabetes Summit, Philadelphia, Pennsylvania, USA, 7th-8th March 2011.  View poster

Henderson AJ et al. Identification of the 5-HT6 antagonist AMR-SIX-1 for the treatment of obesity. Keystone Symposium, Obesity, Keystone, Colorado, USA, 12th-17th January 2011.  View poster

Poucher SM et al. Preservation of pancreatic beta cell-mass in high fat-fed STZ treated mice by the dipeptidyl peptidase-4 inhibitors saxagliptin and sitagliptin. Poster No. 567. European Association for the Study of Diabetes (EASD), Stockholm, Sweden, 20th-24th September 2010. View poster

Grempler R et al. Weight loss Induced by the potent and selective SGLT-2 inhibitor, BI 10773, is due to body fat reduction - studies in dietary-induced obese rats. Abstract No. 1793-P. American Diabetes Association 70th Scientific Sessions, Orlando, Florida, USA, 25th-29th June 2010.  View poster

Cheetham SC et al. Effect of the MCH1 antagonist, GW803430, on body weight, food and water intake, glucose tolerance, fat pad weight, ex vivo binding and various plasma parameters in dietary-induced obese C57BL/6J mice. Program No. 584.24. Society for Neuroscience Meeting, Washington, DC, USA, 15th-19th November 2008.  View poster

Heal DJ et al. Prevention of antipsychotic-induced weight-gain by the 5-HT6 agonist, E-6837. Program No. 584.12. Society for Neuroscience Meeting, Washington, DC, USA, 15th-19th November 2008.  View poster

Vickers SP et al. Effect of rimonabant on body weight, glucose tolerance, body composition and lipolysis in fa/fa Zucker rats: A comparison with pair-fed controls. Program No. 584.18. Society for Neuroscience Meeting, Washington, DC, USA, 15th-19th November 2008.  View poster

Jackson HC et al. Effect of chronic administration of topiramate and phentermine alone and in combination in an animal model of dietary induced obesity. Program No. 629.15. Society for Neuroscience Meeting, San Diego, California, USA, 3rd-7th November 2007.  View poster

Shacham S et al. PRX-07034, a potent and selective 5-HT6 receptor antagonist, reduces food intake and body weight in dietary-induced obese rats. Program No. 62.10. Society for Neuroscience Meeting, Atlanta, Georgia, USA, 14th-18th October, 2006.  View poster

Jackson HC et al. Comparison of the effects of rimonabant and sibutramine in a rat model of dietary induced obesity. Program No. 532.13. Society for Neuroscience Meeting, Washington, DC, USA, 12th-16th November 2005.  View poster

Vickers SP et al. Comparison of the effects of rimonabant, sibutramine and orlistat on acute food intake and in a model of dietary induced obesity in the mouse. Program No. 532.12. Society for Neuroscience Meeting, Washington, DC, USA, 12th-16th November 2005.  View poster

Jackson HC et al. Comparison of the effects of sibutramine and orlistat on body weight, food and water intake and body composition in dietary-induced obese rats.  Program No. 76.19. Society for Neuroscience Meeting, San Diego, California, USA, 23rd-27th October 2004.  View poster